查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1782000

生物相似藥和生物製劑市場，按產品類型、按應用、按分銷、按製造類型、按國家和地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測

Biosimilar and Biologics Market, By Product Type, By Application, By Distribution, By Manufacturing Type, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 269 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

2024 年生物相似藥和生物製劑市場規模價值 5,563.0944 億美元，2025 年至 2032 年的複合年成長率為 7.81%。

生物相似藥和生物製劑市場-市場動態

重磅生物製劑專利到期

生物相似藥市場最重要的成長動力之一是主要生物製劑專利到期。這些生物製劑通常被稱為“重磅炸彈”，每年創造數十億美元的銷售額。專利到期後，生物相似藥製造商有機會開發和銷售更經濟實惠的替代藥物。例如，阿達木單抗（Humira）是全球最暢銷的生物製劑之一，用於治療類風濕性關節炎和克隆氏症，在生物相似藥進入市場之前，其年收入超過200億美元。重磅生物製劑專利到期是生物相似藥市場成長的根本驅動力。它促進了競爭，降低了藥品價格，並擴大了生物療法的可近性，最終建立了一個更永續的全球醫療保健體系。隨著越來越多的生物製劑失去獨佔權，這一趨勢將在未來十年持續下去，為生物相似藥的開發和應用鋪平道路。

生物相似藥和生物製劑市場—關鍵見解

根據我們的研究分析師的分析，預計全球市場在預測期內（2025-2032 年）的年複合成長率約為 7.81%。

根據產品類型細分，預計生物製劑將在 2024 年佔據最大市場佔有率

根據應用細分，腫瘤學是 2024 年的領先應用

根據分銷細分，醫院藥局是 2024 年的主要分銷管道

按地區分類，北美是 2024 年的主要收入來源

生物相似藥和生物製劑市場細分分析：

全球生物相似藥和生物製劑市場根據產品類型、應用、分銷、製造類型和地區進行細分。

根據產品類型，市場分為兩類：生物製劑和生物相似藥。生物製劑是由生物體製成的原創複雜藥物，用於治療癌症和自體免疫疾病等疾病。生物相似藥是與已核准的生物製劑高度相似、成本較低的版本，是在原廠藥專利到期後開發的，具有同等的安全性和有效性。

根據應用，市場分為兩類：腫瘤學、傳染病、自體免疫疾病（如類風濕性關節炎、牛皮癬）、血液疾病（如貧血、血友病）、糖尿病、生長激素缺乏症、眼科疾病（如黃斑部病變）和其他（如罕見疾病、生育治療）。癌症是全球主要死亡原因之一，由於人口老化、生活方式改變和診斷技術的進步，癌症發生率不斷上升。生物製劑，尤其是單株抗體和標靶治療，透過提供個人化、有效且比傳統化療副作用更少的解決方案，徹底改變了癌症治療。此外，腫瘤學在生物製劑和生物相似藥的研發投資、臨床試驗和監管批准中佔很大佔有率，鞏固了其主導地位。隨著癌症病例預計將增加以及對精準醫療的關注度不斷提高，腫瘤學很可能仍將是該市場中最苛刻和最有利可圖的應用領域。

生物相似藥和生物製劑市場—地理洞察

生物相似藥和生物製劑市場在不同地理區域呈現不同的成長模式。北美，尤其是美國，憑藉其先進的醫療基礎設施、強勁的研發投入以及關鍵製藥企業的佈局，在生物製劑市場佔據重要佔有率。儘管由於監管和市場壁壘，美國生物相似藥的採用最初進展緩慢，但隨著修美樂（Humira）等重磅藥物專利到期，這一進程正在加速。歐洲是生物相似藥最成熟、最成熟的市場，這得益於其成本控制政策、歐洲藥品管理局（EMA）的支持性監管框架以及醫生和患者的高接受度。亞太地區是成長最快的地區，印度、中國和韓國等國家正成為主要的生物相似藥製造商。龐大的患者群體、日益成長的醫療服務可及性以及不斷完善的監管途徑推動了這一成長。在拉丁美洲，隨著各國推動醫療體系現代化並鼓勵使用生物相似藥以減少公共支出，市場正在穩步擴張。最後，中東和非洲代表著新興市場，對平價生物製劑的需求不斷成長，儘管其可及性和基礎設施方面仍存在挑戰。總體而言，儘管歐洲在生物相似藥的採用方面處於領先地位，但北美和亞太地區將推動未來的市場成長。

生物相似藥和生物製劑市場—競爭格局：

生物相似藥和生物製劑市場的競爭格局以老牌製藥巨頭和新興生物技術公司之間的激烈競爭為特徵。安進、輝瑞、羅氏、諾華（山德士）、三星Bioepis、Biocon、Celltrion和邁蘭（Viatris）等主要參與者佔據市場主導地位，利用強大的研發能力、廣泛的生產設施和全球分銷網路來維持和擴大其市場佔有率。這些公司正在大力投資開發生物相似藥，用於那些專利已過期或即將過期的高需求生物製劑。競爭不僅基於價格，還基於產品品質、監管部門的批准、專利策略以及旨在建立醫生和患者信任的行銷策略。此外，策略合作夥伴關係、合作以及併購也是常見的做法，旨在增強產品線組合併進入新市場。由於監管要求和市場准入存在地區差異，市場格局進一步複雜化，這影響了公司在全球範圍內定位其生物相似藥的方式。隨著市場的發展，生物加工技術和客製化療法的創新對於希望在這個快速成長的領域中保持競爭力的公司至關重要。

最新動態：

2025年3月，費森尤斯卡比（Fresenius Kabi）的兩種地舒單抗生物相似藥Conexxence和Bomyntra獲得美國FDA批准，目前這兩款藥物分別獲批用於與原參比藥物Prolia和Xgeva相同的適應症。此核准為骨質疏鬆症和癌症相關骨質疏鬆症患者提供了更豐富的治療選擇，有助於提升美國市場對生物相似藥的接受度。

目錄

第1章：生物相似藥和生物製劑市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 生物相似藥和生物製劑市場片段（按產品類型）
    • 生物相似藥和生物製劑市場片段（按應用）
    • 生物相似藥和生物製劑市場片段（按分佈）
    • 生物相似藥和生物製劑市場片段（按製造類型）
    • 生物相似藥和生物製劑市場（按國家/地區）
    • 生物相似藥和生物製劑市場（按地區）
  • 競爭洞察

第3章：生物相似藥和生物製劑的主要市場趨勢

  • 生物相似藥和生物製劑市場促進因素
    • 市場促進因素的影響分析
  • 生物相似藥和生物製劑市場限制
    • 市場限制的影響分析
  • 生物相似藥和生物製劑的市場機會
  • 生物相似藥和生物製劑市場未來趨勢

第4章：生物相似藥和生物製劑產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：生物相似藥和生物製劑市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：生物相似藥和生物製劑市場格局

  • 2024 年生物相似藥和生物製劑市場佔有率分析
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：生物相似藥和生物製劑市場－依產品類型

  • 概述
    • 按產品類型分類的細分市場佔有率分析
    • 生物製劑：
      • 單株抗體（mAb）
      • 疫苗
      • 重組激素（如胰島素、人類生長激素）
      • 治療性蛋白質（例如促紅血球生成素、干擾素）
      • 血液製品
      • 基因治療
      • 細胞療法
    • 生物相似藥：
      • 單株抗體生物相似藥
      • 重組激素生物相似藥（如胰島素、生長激素）
      • 促紅血球生成素生物相似藥
      • 非格司亭和培非格司亭生物相似藥
      • 英夫利西單抗、阿達木單抗、曲妥珠單抗生物相似藥
      • 干擾素生物相似藥

第 8 章：生物相似藥和生物製劑市場 - 按應用

  • 概述
    • 按應用細分市場佔有率分析
    • 腫瘤學
    • 傳染病
    • 自體免疫疾病（例如類風濕性關節炎、牛皮癬）
    • 血液疾病（如貧血、血友病）
    • 糖尿病
    • 生長激素缺乏症
    • 眼科疾病（如黃斑部病變）
    • 其他（如罕見疾病、生育治療）

第9章：生物相似藥和生物製劑市場－依分佈

  • 概述
    • 按分佈細分市場佔有率分析
    • 醫院藥房
    • 網路藥局
    • 零售藥局

第 10 章：生物相似藥和生物製劑市場 - 按製造類型

  • 概述
    • 按製造類型分類的細分市場佔有率分析
    • 內部製造
    • 合約製造組織（CMO）

第 11 章：生物相似藥和生物製劑市場 - 按地域分類

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美生物相似藥和生物製劑主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模和預測（按產品類型）
    • 北美市場規模和預測（按應用）
    • 北美市場規模和預測（按分佈）
    • 北美市場規模和預測（按技術）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲生物相似藥和生物製劑主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模和預測（按產品類型）
    • 歐洲市場規模和預測，按應用
    • 歐洲市場規模及預測（按分佈）
    • 歐洲市場規模與預測（按技術）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區生物相似藥和生物製劑主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（依產品類型）
    • 亞太地區市場規模及預測（按應用）
    • 亞太地區市場規模及預測（依分佈）
    • 亞太地區市場規模及預測（依技術）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲生物相似藥和生物製劑主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（依產品類型）
    • 拉丁美洲市場規模及預測（按應用）
    • 拉丁美洲市場規模及預測（依分佈）
    • 拉丁美洲市場規模及預測（按技術）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲（MEA）
    • 概述
    • 中東和非洲的生物相似藥和生物製劑主要製造商
    • MEA 市場規模及預測（依國家/地區）
    • MEA 市場規模及預測（依產品類型）
    • MEA 市場規模及預測（按應用）
    • MEA 市場規模及預測（依分佈）
    • MEA 市場規模及預測（依技術）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 12 章：關鍵供應商分析-生物相似藥和生物製劑產業

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • Amgen Inc.
    • Novartis AG (Sandoz)
    • Pfizer Inc.
    • Roche Holding AG
    • Samsung Bioepis
    • Biocon Ltd.
    • Mylan NV (Viatris)
    • Celltrion Inc.
    • Fresenius Kabi
    • Boehringer Ingelheim
    • Cipla Limited
    • Teva Pharmaceutical Industries Ltd.
    • Sandoz (a Novartis division)
    • Dr. Reddy's Laboratories
    • Intas Pharmaceuticals Ltd.
    • Zhejiang Hisun Pharmaceutical Co., Ltd.
    • LG Chem Life Sciences
    • Pfizer Inc.
    • Hetero Drugs Limited
    • Oncobiologics, Inc.
    • Others

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV5382

REPORT HIGHLIGHT

Biosimilar and Biologics Market size was valued at US$ 556,309.44 Million in 2024, expanding at a CAGR of 7.81% from 2025 to 2032.

The biosimilars and biologics market represents one of the fastest-growing sectors in the global pharmaceutical industry. Biologics are large, complex molecules or mixtures of molecules derived from living cells used in the treatment, diagnosis, or prevention of diseases. Examples include monoclonal antibodies, vaccines, and recombinant proteins. Fueled by advances in biotechnology, rising prevalence of chronic diseases, patent expirations of blockbuster biologics, and increasing healthcare costs, the market is witnessing rapid transformation.

Biosimilar and Biologics Market- Market Dynamics

Patent Expiration of Blockbuster Biologics

One of the most significant growth drivers in the biosimilars market is the expiration of patents for major biologic drugs. These biologics, often called "blockbusters", generate billions in annual sales. When their patents expire, it opens the door for biosimilar manufacturers to develop and market more affordable alternatives. For instance, Adalimumab (Humira), one of the world's top-selling biologics used to treat rheumatoid arthritis and Crohn's disease, generated over $20 billion/year in revenue before biosimilars entered the market. The expiration of patents on blockbuster biologics is a fundamental driver of growth in the biosimilar market. It enables competition, reduces drug prices, and expands access to biologic therapies-ultimately creating a more sustainable global healthcare system. This trend will continue over the next decade as more biologics lose exclusivity, paving the way for a surge in biosimilar development and adoption.

Biosimilar and Biologics Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.81% over the forecast period (2025-2032)

Based on product type segmentation, Biologics was predicted to show maximum market share in the year 2024

Based on application segmentation, Oncology was the leading application in 2024

Based on distribution segmentation, Hospital Pharmacies was the leading distribution in 2024

On the basis of region, North America was the leading revenue generator in 2024

Biosimilar and Biologics Market- Segmentation Analysis:

The Global Biosimilar and Biologics Market is segmented on the basis of Product Type, Application, Distribution, Manufacturing Type, and Region.

The market is divided into two categories based on product type: Biologics, and Biosimilars. Biologics and Biosimilars. Biologics are original, complex medicines made from living organisms, used to treat diseases like cancer and autoimmune disorders. Biosimilars are highly similar, lower-cost versions of approved biologics, developed after the original product's patent expires, offering comparable safety and effectiveness.

The market is divided into two categories based on application: Oncology, Infectious Diseases, Autoimmune Diseases (e.g., rheumatoid arthritis, psoriasis), Blood Disorders (e.g., anemia, hemophilia), Diabetes, Growth Hormone Deficiency, Ophthalmic Disorders (e.g., macular degeneration) and Others (e.g., rare diseases, fertility treatments). Cancer is one of the leading causes of death globally, with a rising incidence due to aging populations, lifestyle changes, and improved diagnostics. Biologics particularly monoclonal antibodies and targeted therapies-have revolutionized cancer treatment by offering personalized, effective solutions with fewer side effects compared to traditional chemotherapy. Additionally, oncology accounts for a large share of R&D investments, clinical trials, and regulatory approvals in both biologics and biosimilars, reinforcing its dominance. With cancer cases projected to rise and the focus on precision medicine growing, oncology will likely remain the most demanding and profitable application area in this market.

Biosimilar and Biologics Market- Geographical Insights

The biosimilar and biologics market shows varying growth patterns across different geographical regions. North America, particularly the United States, holds a major share in the biologics market due to advanced healthcare infrastructure, strong R&D investments, and the presence of key pharmaceutical players. Although biosimilar adoption was initially slow in the U.S. due to regulatory and market barriers, it is now accelerating following the expiration of patents for blockbuster drugs like Humira. Europe is the most mature and established market for biosimilars, driven by cost-containment policies, supportive regulatory frameworks by the European Medicines Agency (EMA), and high physician and patient acceptance. Asia-Pacific is the fastest-growing region, with countries like India, China, and South Korea emerging as major biosimilar manufacturers. This growth is supported by large patient populations, increasing healthcare access, and improving regulatory pathways. In Latin America, the market is expanding steadily as countries modernize their healthcare systems and encourage biosimilar use to reduce public spending. Lastly, the Middle East and Africa represent emerging markets with growing demand for affordable biologic treatments, although access and infrastructure challenges remain. Overall, while Europe leads in biosimilar adoption, North America and Asia-Pacific are set to drive future market growth.

Biosimilar and Biologics Market- Competitive Landscape:

The competitive landscape of the biosimilars and biologics market is characterized by intense rivalry among a mix of established pharmaceutical giants and emerging biotech companies. Major players like Amgen, Pfizer, Roche, Novartis (Sandoz), Samsung Bioepis, Biocon, Celltrion, and Mylan (Viatris) dominate the market, leveraging strong R&D capabilities, extensive manufacturing facilities, and global distribution networks to maintain and expand their market share. These companies are investing heavily in developing biosimilars for high-demand biologics whose patents have expired or are nearing expiration. Competition is not only based on pricing but also on product quality, regulatory approvals, patent strategies, and marketing efforts to build physician and patient trust. Additionally, strategic partnerships, collaborations, and mergers and acquisitions are common to enhance pipeline portfolios and access new markets. The landscape is further complicated by regional differences in regulatory requirements and market access, which influence how companies position their biosimilar products worldwide. As the market evolves, innovation in bioprocessing technologies and tailored therapies will be crucial for companies aiming to stay competitive in this rapidly growing sector.

Recent Developments:

In March 2025, Fresenius Kabi received U.S. FDA approval for two of their denosumab biosimilars, Conexxence and Bomyntra, which are now approved for the same indications as the original reference drugs, Prolia and Xgeva, respectively. This approval enhances treatment options for patients with osteoporosis and cancer-related bone loss, contributing to the growing acceptance of biosimilars in the U.S. market .

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Amgen Inc.
  • Novartis AG (Sandoz)
  • Pfizer Inc.
  • Roche Holding AG
  • Samsung Bioepis
  • Biocon Ltd.
  • Mylan N.V. (Viatris)
  • Celltrion Inc.
  • Fresenius Kabi
  • Boehringer Ingelheim
  • Cipla Limited
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz (a Novartis division)
  • Dr. Reddy's Laboratories
  • Intas Pharmaceuticals Ltd.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • LG Chem Life Sciences
  • Pfizer Inc.
  • Hetero Drugs Limited
  • Oncobiologics, Inc.
  • Others

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

Biologics:

  • Monoclonal Antibodies (mAbs)
  • Vaccines
  • Recombinant Hormones (e.g., insulin, human growth hormone)
  • Therapeutic Proteins (e.g., erythropoietin, interferons)
  • Blood Products
  • Gene Therapy
  • Cell Therapy

Biosimilars:

  • Monoclonal Antibodies Biosimilars
  • Recombinant Hormones Biosimilars (e.g., insulin, growth hormone)
  • Erythropoietin Biosimilars
  • Filgrastim and Pegfilgrastim Biosimilars
  • Infliximab, Adalimumab, Trastuzumab Biosimilars
  • Interferons Biosimilars

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Oncology
  • Infectious Diseases
  • Autoimmune Diseases (e.g., rheumatoid arthritis, psoriasis)
  • Blood Disorders (e.g., anemia, hemophilia)
  • Diabetes
  • Growth Hormone Deficiency
  • Ophthalmic Disorders (e.g., macular degeneration)
  • Others (e.g., rare diseases, fertility treatments)

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY MANUFACTURING TYPE- MARKET ANALYSIS, 2019 - 2032

  • In-house Manufacturing
  • Contract Manufacturing Organizations (CMOs)

GLOBAL BIOSIMILAR AND BIOLOGICS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Biosimilar and Biologics Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Biosimilar and Biologics Market Snippet by Product Type
    • 2.1.2. Biosimilar and Biologics Market Snippet by Application
    • 2.1.3. Biosimilar and Biologics Market Snippet by Distribution
    • 2.1.4. Biosimilar and Biologics Market Snippet by Manufacturing Type
    • 2.1.5. Biosimilar and Biologics Market Snippet by Country
    • 2.1.6. Biosimilar and Biologics Market Snippet by Region
  • 2.2. Competitive Insights

3. Biosimilar and Biologics Key Market Trends

  • 3.1. Biosimilar and Biologics Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Biosimilar and Biologics Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Biosimilar and Biologics Market Opportunities
  • 3.4. Biosimilar and Biologics Market Future Trends

4. Biosimilar and Biologics Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Biosimilar and Biologics Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Biosimilar and Biologics Market Landscape

  • 6.1. Biosimilar and Biologics Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Biosimilar and Biologics Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
    • 7.1.2. Biologics:
      • 7.1.2.1. Monoclonal Antibodies (mAbs)
      • 7.1.2.2. Vaccines
      • 7.1.2.3. Recombinant Hormones (e.g., insulin, human growth hormone)
      • 7.1.2.4. Therapeutic Proteins (e.g., erythropoietin, interferons)
      • 7.1.2.5. Blood Products
      • 7.1.2.6. Gene Therapy
      • 7.1.2.7. Cell Therapy
    • 7.1.3. Biosimilars:
      • 7.1.3.1. Monoclonal Antibodies Biosimilars
      • 7.1.3.2. Recombinant Hormones Biosimilars (e.g., insulin, growth hormone)
      • 7.1.3.3. Erythropoietin Biosimilars
      • 7.1.3.4. Filgrastim and Pegfilgrastim Biosimilars
      • 7.1.3.5. Infliximab, Adalimumab, Trastuzumab Biosimilars
      • 7.1.3.6. Interferons Biosimilars

8. Biosimilar and Biologics Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 8.1.2. Oncology
    • 8.1.3. Infectious Diseases
    • 8.1.4. Autoimmune Diseases (e.g., rheumatoid arthritis, psoriasis)
    • 8.1.5. Blood Disorders (e.g., anemia, hemophilia)
    • 8.1.6. Diabetes
    • 8.1.7. Growth Hormone Deficiency
    • 8.1.8. Ophthalmic Disorders (e.g., macular degeneration)
    • 8.1.9. Others (e.g., rare diseases, fertility treatments)

9. Biosimilar and Biologics Market - By Distribution

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution, 2024 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Online Pharmacies
    • 9.1.4. Retail Pharmacies

10. Biosimilar and Biologics Market - By Manufacturing Type

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Manufacturing Type, 2024 & 2032 (%)
    • 10.1.2. In-house Manufacturing
    • 10.1.3. Contract Manufacturing Organizations (CMOs)

11. Biosimilar and Biologics Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Biosimilar and Biologics Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Biosimilar and Biologics Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.9. UK
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.9.5. UK Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.9.6. UK Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.10. France
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.10.5. France Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.10.6. France Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.11. Italy
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.11.5. Italy Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.11.6. Italy Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.12. Spain
      • 11.3.12.1. Overview
      • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Spain Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.12.6. Spain Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.13. The Netherlands
      • 11.3.13.1. Overview
      • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.13.4. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.13.5. The Netherlands Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.13.6. The Netherlands Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Overview
      • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.14.6. Sweden Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.15. Russia
      • 11.3.15.1. Overview
      • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Russia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.15.6. Russia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.16. Poland
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Poland Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Poland Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.3.17. Rest of Europe
      • 11.3.17.1. Overview
      • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.17.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.3.17.5. Rest of the Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.3.17.6. Rest of the Europe Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Biosimilar and Biologics Key Manufacturers in Asia Pacific
    • 11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.4.5. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.4.6. APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.4.7. APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.8. China
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.8.5. China Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.8.6. China Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.9. India
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.9.5. India Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.9.6. India Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.13. Indonesia
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Indonesia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Indonesia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.14. Thailand
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Thailand Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Thailand Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.5. Latin America (LATAM)
    • 11.5.1. Overview
    • 11.5.2. Biosimilar and Biologics Key Manufacturers in Latin America
    • 11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.5.5. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.5.6. LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.5.7. LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa (MEA)
    • 11.6.1. Overview
    • 11.6.2. Biosimilar and Biologics Key Manufacturers in Middle East and Africa
    • 11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.6.5. MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 11.6.6. MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 11.6.7. MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By Technology, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Biosimilar and Biologics Industry

  • 12.1. Competitive Dashboard
    • 12.1.1. Competitive Benchmarking
    • 12.1.2. Competitive Positioning
  • 12.2. Company Profiles
    • 12.2.1. Amgen Inc.
    • 12.2.2. Novartis AG (Sandoz)
    • 12.2.3. Pfizer Inc.
    • 12.2.4. Roche Holding AG
    • 12.2.5. Samsung Bioepis
    • 12.2.6. Biocon Ltd.
    • 12.2.7. Mylan N.V. (Viatris)
    • 12.2.8. Celltrion Inc.
    • 12.2.9. Fresenius Kabi
    • 12.2.10. Boehringer Ingelheim
    • 12.2.11. Cipla Limited
    • 12.2.12. Teva Pharmaceutical Industries Ltd.
    • 12.2.13. Sandoz (a Novartis division)
    • 12.2.14. Dr. Reddy's Laboratories
    • 12.2.15. Intas Pharmaceuticals Ltd.
    • 12.2.16. Zhejiang Hisun Pharmaceutical Co., Ltd.
    • 12.2.17. LG Chem Life Sciences
    • 12.2.18. Pfizer Inc.
    • 12.2.19. Hetero Drugs Limited
    • 12.2.20. Oncobiologics, Inc.
    • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us